In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BI, Vectura develop inhaler for respiratory diseases; ends

Executive Summary

Boehringer Ingelheim will work with Vectura Group (inhaled compounds and device technologies for lung diseases) to develop a branded dry powder inhaler (DPI) delivering BI's compounds primarily as asthma and chronic obstructive pulmonary disease (COPD) treatments. BI makes a 3.8% equity investment in Vectura.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies